Loading
Breast Cancer / Lung Cancer / Prostate Cancer · Observational Study
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active observational biobank study at the National Cancer Institute enrolling ~1100 patients with cancer to collect blood or cheek swab samples for genomic analysis of treatment-related genetic variation. No clinical outcomes, efficacy data, or results are reported in this registry record.
Observational. Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma; age from 3 Years. Intervention: 1/ Patients with cancer, other tumors, or possible genetic…. n = 1,100. 1 site: United States.
This is an active observational biobank study at the National Cancer Institute enrolling ~1100 patients with cancer to collect blood or cheek swab samples for genomic analysis of treatment-related genetic variation. No clinical outcomes, efficacy data, or results are reported in this registry record.
Genetic variants associated with treatment side effects or efficacy are hypothesized but not yet analysed in this record.
The source did not state who this applies to in practice.
This is an active observational registry study collecting biosamples for genetic analysis with no results posted; it represents a descriptive, specimen-collection protocol without outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT01441089). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 1100 participants (ESTIMATED). Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma. Primary outcome measures: Obtain and analyze the genomic DNA from patients with cancer, other tumors, or possible genetic tumor predisposition syndromes on a therapeutic clinical trial. , duration of study. Brief summary: Background: \- Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: \- To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: \- Individuals with cancer who are being treated at the National Cancer Institute. Design: * Participants will provide a blood sample for study. * Participants who have blood-based cancer, such as leukemia, will provide a cheek swab sample. * If the blood or cheek swab sample does not have enough genetic material for analysis, an additional sample may be collected.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.